Rheumatology A
CASPAR Criteria for Psoriatic Arthritis
Classification criteria for psoriatic arthritis (PsA). Requires inflammatory articular disease + score ≥3.
Score interpretation
PsA Not Classified 0–2
Score <3: Does not meet CASPAR criteria for PsA
→ Consider seronegative RA, reactive arthritis, or gout; dermatology review if psoriasis suspected
Psoriatic Arthritis Classified 3–7
Score ≥3: Meets CASPAR criteria for psoriatic arthritis
→ Rheumatology referral; DMARDs (methotrexate first-line); consider biologic if inadequate response; dermatology co-management for skin disease
Interpretation bands for the CASPAR. Apply clinical judgement and local guidance.
References
- Taylor W, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Deucravacitinib (TYK2 Inhibitor — Psoriatic Arthritis/Psoriasis) · Selective TYK2 Inhibitor (Allosteric — Regulatory Domain Binding)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Salicylic Acid · Keratolytic — Warts / Psoriasis / Hyperkeratosis
- Ixekizumab · IL-17A Inhibitor — Psoriasis
- Guselkumab · IL-23 Inhibitor — Psoriasis
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.